Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Synairgen plc
With a candidate COVID-19 therapy in clinical development, the UK’s Synairgen has raised $101m on the UK’s AIM to support clinical studies and manufacturing plans.
Walmsley has been awarded a damehood in the Queen’s Birthday Honours List. Meanwhile, Synairgen co-founder Holgate is to become a Sir.
Drugs that have failed in clinical studies often come back for another go, making the same mistakes for a new cohort of investors who missed the first failure. The global pandemic is also enabling this for once- or twice-failed drugs.
Disappointment as Roche/Chugai antibody tocilizumab misses most endpoints.
- Drug Discovery Tools
- Large Molecule
Drug Discovery Tools
- Other Names / Subsidiaries
- Synairgen Research Ltd